Bifunctional black phosphorus quantum dots platform: Delivery and remarkable immunotherapy enhancement of STING agonist

• Published in: Biomaterials 2024-12, Vol.311, p.122696, Article 122696
• Main Authors: Zhang, Yujun, Wang, Shijing, Rha, Hyeonji, Xu, Chang, Pei, Yue, Ji, Xiaoyuan, Zhang, Junmin, Lu, Ruitao, Zhang, Shaochong, Xie, Zhongjian, Kim, Jong Seung
• Format: Article
• Language: English
• Subjects: Animals; Black phosphorus quantum dots; Cell Line, Tumor; Cytokines - metabolism; Drug Delivery Systems; Female; Humans; Immunotherapy; Immunotherapy - methods; Membrane Proteins - agonists; Mice; Mice, Inbred C57BL; Mild photothermal therapy (PTT); Phosphorus - chemistry; Photothermal Therapy - methods; Quantum Dots - chemistry; STING agonist; Targeted delivery
• ISSN: 0142-9612; 1878-5905; 1878-5905
• DOI: 10.1016/j.biomaterials.2024.122696

Cancer immunotherapy has been developed to improve therapeutic effects for patients by activating the innate immune stimulator of interferon gene (STING) pathway. However, most patients cannot benefit from this therapy, mainly due to the problems of excessively low immune responses and lack of tumor specificity. Herein, we report a solution to these two problems by developing a bifunctional platform of black phosphorus quantum dots (BPQDs) for STING agonists. Specifically, BPQDs could connect targeted functional groups and regulate surface zeta potential by coordinating metal ions to increase loading (over 5 times) while maintaining high universality (7 STING agonists). The controlled release of STING agonists enabled specific interactions with their proteins, activating the STING pathway and stimulating the secretion release of immunosuppressive factors by phosphorylating TBK1 and IFN-IRF3 and secreting high levels of immunostimulatory cytokines, including IL-6, IFN-α, and IFN-β. Moreover, the immunotherapy was enhanced was enhanced mild photothermal therapy (PTT) of BPQDs platform, producing enough T cells to eliminate tumors and prevent tumor recurrence. This work facilitates further research on targeted delivery of small-molecule immune drugs to enhance the development of clinical immunotherapy.